GleamWall
中文EN

MENS Jyong Biotech Ltd. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1954488

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-54.7%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-34.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets219.9%
Debt / equity—
Current ratio0.45x
Interest coverage-1.03x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$813,000$927,000
SG&A expense$1.75M$1.08M
Operating income-$2.61M-$2.06M
Interest expense$2.54M$1.03M
Pretax income-$4.67M-$3.02M
Net income-$4.67M-$3.02M
EBITDA-$2.51M-$1.94M
EPS (basic)-0.06-0.04
EPS (diluted)-0.06-0.04
Weighted avg. shares (diluted)73.01M71.57M
Balance sheet
Cash & equivalents$1.18M$101,000
Current assets$15.54M$206,000
PP&E, net$3.09M$3.05M
Total assets$20.78M$6.37M
Current liabilities$34.81M$12.13M
Short-term debt$15.34M—
Long-term debt$2.12M—
Total debt$17.46M—
Total liabilities$45.68M$42.88M
Shareholders' equity-$24.91M-$36.52M
Net debt$16.28M—
Shares outstanding76.03M73.36M
Cash flow statement
Operating cash flow-$3.04M-$3.62M
Investing cash flow-$13.51M—
Financing cash flow$17.63M$1.99M
Depreciation & amortization$100,000$120,000

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.